Axa
SVRA icon

Axa’s Savara SVRA Stock Holding History

Axa’s Portfolio SVRA Stock Details SVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,050,126
Closed -$2.39M – 900
2025
Q2 		$2.39M Buy
1,050,126
+1,685
+0.2% +$4.58K 0.01% 738
2025
Q1 		$2.9M Sell
1,048,441
-1,334
-0.1% -$3.68K 0.01% 662
2024
Q4 		$3.22M Sell
1,049,775
-1,657
-0.2% -$5.78K 0.01% 659
2024
Q3 		$4.46M Buy
1,051,432
+297
+0% +$1.31K 0.01% 576
2024
Q2 		$4.24M Sell
1,051,135
-279,300
-21% -$1.24M 0.01% 577
2024
Q1 		$6.63M Sell
1,330,435
-417,238
-24% -$2.02M 0.02% 494
2023
Q4 		$8.21M Sell
1,747,673
-42,275
-2% -$162K 0.03% 440
2023
Q3 		$6.77M Sell
1,789,948
-496,455
-22% -$1.77M 0.02% 473
2023
Q2 		$7.31M Sell
2,286,403
-542,927
-19% -$1.28M 0.02% 476
2023
Q1 		$5.52M Sell
2,829,330
-578,557
-17% -$1.3M 0.02% 541
2022
Q4 		$5.28M Sell
3,407,887
-18,328
-0.5% -$25.1K 0.02% 582
2022
Q3 		$5.31M Buy
3,426,215
+14,736
+0.4% +$23.7K 0.02% 564
2022
Q2 		$5.19M Sell
3,411,479
-66,353
-2% -$87.2K 0.02% 572
2022
Q1 		$4.56M Buy
3,477,832
+37
+0% +$45 0.01% 663
2021
Q4 		$4.31M Buy
3,477,795
+412,491
+13% +$491K 0.01% 697
2021
Q3 		$4.23M Buy
3,065,304
+113,074
+4% +$153K 0.01% 725
2021
Q2 		$5.02M Sell
2,952,230
-224,192
-7% -$403K 0.01% 709
2021
Q1 		$6.61M Buy
3,176,422
+1,280,868
+68% +$2.19M 0.02% 629
2020
Q4 		$2.18M Buy
1,895,554
+491,035
+35% +$592K 0.01% 836
2020
Q3 		$1.53M Sell
1,404,519
-7,718
-0.5% -$13.2K 0.01% 863
2020
Q2 		$3.52M Buy
1,412,237
+71,241
+5% +$173K 0.01% 706
2020
Q1 		$2.84M Buy
+1,340,996
New +$3.68M 0.01% 662

Other funds holding SVRA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Axa's SVRA Position: Q3 2025 in Review

Axa sold out of Savara (SVRA) in Q3 2025, closing a stake of 1,050,126 shares — an estimated $2.39M sold.

Axa first reported a position in SVRA in Q1 2020 and held it in 22 quarters. The position peaked at $8.21M in Q4 2023. 126 funds tracked by Wall St. Rank hold SVRA as of Q3 2025.

  • Axa reported no remaining Savara position as of Q3 2025 after selling out during the quarter.
  • Axa sold 1,050,126 Savara shares in Q3 2025, an estimated $2.39M.
  • Axa first reported a position in Savara in Q1 2020 and held it in 22 quarters.
  • Axa's Savara position peaked at $8.21M in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Savara as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.